Novartis (NOVN.SW) stock price, revenue, and financials

Novartis market cap is CHF189.9 b, and annual revenue was $49.11 b in FY 2017

CHF189.9 B

NOVN.SW Mkt cap, 20-May-2020

$49.1 B

Novartis Revenue FY, 2017
Novartis Revenue growth (FY, 2016 - FY, 2017), %1%
Novartis Gross profit (FY, 2017)31.9 B
Novartis Gross profit margin (FY, 2017), %65%
Novartis Net income (FY, 2017)7.7 B
Novartis Cash, 31-Dec-20178.9 B

Novartis Revenue

Novartis revenue was $49.11 b in FY, 2017 which is a 1.2% year over year increase from the previous period.

Embed Graph

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 67.2% from Innovative Medicines, 20.5% from Sandoz and 12.3% from Alcon

Novartis revenue breakdown by geographic segment: 34.5% from United States, 7.5% from Germany, 5.1% from France, 6.5% from Japan and 46.5% from Other

Novartis Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

49.4b48.5b49.1b

Revenue growth, %

(8%)(2%)1%

Cost of goods sold

17.4b17.5b17.2b

Gross profit

32.0b31.0b31.9b

Gross profit Margin, %

65%64%65%

Sales and marketing expense

11.8b12.0b12.9b

R&D expense

8.9b9.0b9.0b

General and administrative expense

2.5b2.2b2.1b

Operating expense total

24.0b23.6b24.3b

Interest expense

655.0m707.0m777.0m

Pre tax profit

8.1b7.8b9.0b

Income tax expense

1.1b1.1b1.3b

Net Income

17.8b6.7b7.7b

Novartis Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

7.0b8.9b

Accounts Receivable

8.2b8.6b

Inventories

6.3b6.9b

Current Assets

24.9b28.2b

PP&E

15.6b16.5b

Goodwill

31.0m31.8b

Total Assets

130.1b133.1b

Accounts Payable

4.9b5.2b

Current Liabilities

22.2b23.4b

Non-Current Liabilities

33.0b35.4b

Total Liabilities

55.2b58.9b

Common Stock

972.0m969.0m

Total Equity

74.9b74.2b

Financial Leverage

1.7 x1.8 x

Novartis Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

7.0b6.7b7.7b

Cash From Operating Activities

11.9b11.5b12.6b

Purchases of PP&E

(2.4b)(1.9b)(1.7b)

Cash From Investing Activities

(10.8b)(3.4b)(3.1b)

Short-term Borrowings

(755.0m)

Long-term Borrowings

(3.1b)(1.7b)(188.0m)

Dividends Paid

(6.6b)(6.5b)(6.5b)

Cash From Financing Activities

(9.2b)(5.3b)(7.7b)

Net Change in Cash

(8.3b)2.3b1.9b

Novartis Ratios

USDY, 2017

Revenue/Employee

403.9k

Financial Leverage

1.8 x

Novartis Operating Metrics

FY, 2015FY, 2016FY, 2017

Major Approvals (US, EU, JP)

20 16 16

Major Submissions (US, EU, JP)

14 24 16

Patients Reached

972 m965 m927 m

Phase III Trials Products

37 29 37

Projects Entering Development Pipeline

8 5 9

US FDA Breakthrough Therapy Designations

5 6

Novartis Employee Rating

3.93984 votes
Culture & Values
3.8
Work/Life Balance
3.8
Senior Management
3.3
Salary & Benefits
3.9
Career Opportunities
3.5
Source